Management ChangeJun 10, 2026, 06:07 AM
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board
AI Summary
Aldeyra Therapeutics announced the appointment of Darlene Deptula-Hicks to its Board of Directors as a Class III director, with her term expiring in 2029. She will also serve as Chair of the Audit Committee and has been determined to be independent and an audit committee financial expert. As part of her compensation, she received a stock option for 94,313 shares and will receive annual fees for her roles. Additionally, the company held its 2026 Annual Meeting where stockholders elected Todd C. Brady as a Class III director, ratified the appointment of BDO USA, P.C. as the independent auditor, and approved executive compensation on an advisory basis.
Key Highlights
- Darlene Deptula-Hicks appointed as Class III director to Aldeyra's Board.
- Ms. Deptula-Hicks appointed Chair of the Audit Committee.
- She is independent and qualifies as an audit committee financial expert.
- Granted a non-statutory stock option to purchase 94,313 shares.
- Will receive an annual director fee of $40,000 and $7,500 as Audit Committee Chair.
- Stockholders elected Todd C. Brady as Class III director.
- Stockholders ratified BDO USA, P.C. as independent auditor for 2026.
- Stockholders approved executive compensation on an advisory basis.
Price Impact
More from ALDX